Stock News

Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
20 Fastest Growing Health Tech Companies in the World
Merck raises 2024 guidance on cancer drug demand
Merck Stock Climbs After Higher-Than-Expected Sales of Cancer Drug Keytruda
UPDATE 3-Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Alphabet, Microsoft, Southwest earnings: What to watch
Here’s Why Merck & Co. (MRK) Outperformed in Q1
10 Best Performing Biotech ETFs in 2024
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

As seen on...